AZD-2171 |
CEDIRANIB |
ZD-2171 |
RECENTIN |
ZD 2171 |
AZD 2171 |
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE |
chembl:CHEMBL491473 |
pubchem.compound:9933475 |
drugbank:04849 |
chemidplus:288383-20-0 |
Pharmaceutical Developer | AstraZeneca |
Source Reported Drug Name(s) | Cediranib maleate/ AZD2171/Recentin |
Drug Class | VEGFR Inhibitor |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Drug Categories | antineoplastic and immunomodulating agents |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Notes | |
Trial Name | cediranib, AZD2171,Recentin |
Novel drug target | Established target |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | cediranib, AZD2171,Recentin |
Notes |
inhibitor (inhibitory) |
Notes | |
Direct Interaction? | True |
Endogenous Drug? | False |
n/a |
Drug family | ALK inhibitor |
Alteration | NF1:del |
Alteration | NF1:. |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
CEDIRANIB | DrugBank Drug Name |
288383-20-0 | CAS Number |
Recentin | Drug Brand |
Drug Type | small molecule |
Drug Groups | investigational |
Drug Categories | antineoplastic agents |
CEDIRANIB | Generic Name |
RECENTIN | Trade Name |
Drug Class | Kinase Inhibitors |
Cediranib maleate | PubChem Drug Name |
11226834 | PubChem Drug ID |
Cediranib | Drug Trade Name |
Drug Class | VEGFR Inhibitor |
Source Reported Drug Name(s) | Cediranib maleate/ AZD2171/Recentin |
Pharmaceutical Developer | AstraZeneca |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CEDIRANIB | Primary Drug Name |
CEDIRANIB | Drug Generic Name |
RECENTIN | Drug Trade Name |
CEDIRANIB | GuideToPharmacology Ligand Name |
CHEMBL491473 | ChEMBL Drug ID |
D09VMI | TTD Drug ID |